The difficulties involved in the production of ADCs act as a restraint on the antibody drug conjugates market. ADC manufacturing facilities necessitate a significant capital investment as well as extensive specialised training for operators. The development of an ADC process is complicated because it necessitates the optimization of additional process steps not found in conventional monoclonal antibody manufacturing, such as the antibody-drug conjugation reaction and subsequent drug substance purification. Furthermore, antibody drug conjugates must be manufactured in aseptic environments, and operating personnel must be protected from highly toxic drug compounds, posing operational challenges.
Furthermore, Asia Pacific is expected to witness significant growth in the global Antibody Drug Conjugates Market over the forecast period due to increasing strategic partnerships among market players. On November 27, 2018, Zymeworks Inc., a clinical-stage biopharmaceutical company, and BeiGene, Ltd., a commercial-stage biopharmaceutical company, announced a strategic partnership for the clinical development and commercialization of bi-specific antibodies ZW25 and ZW49 HER2. Zymeworks granted BeiGene the exclusive right to develop and commercialise the clinical-stage bi-specific antibody candidate ZW49 and its preclinical-stage bi-specific antibody drug conjugate (ADC) ZW49 in Asia (excluding Japan), Australia, and New Zealand.
Read More@ https://bit.ly/3prmxrt